Pulmonary vasomotor dysfunction is produced with chronically high pulmonary blood flow  by Fullerton, David A. et al.
PULMONARY VASOMOTOR 
DYSFUNCTION IS 
PRODUCED WITH 
CHRONICALLY HIGH 
PULMONARY BLOOD FLOW 
This study examined the hypothesis that chronic high pulmonary blood flow 
produces dysfunction of the mechanisms of pulmonary vasorelaxation. A
3:1 left-to-right shunt was created in dogs by bilateral femoral artery- 
femoral vein shunts with use of 6 mm polytetrafluoroethylene grafts. 
Isolated pulmonary artery rings were studied at the following times: 3 days 
(n = 2), 2 weeks (n = 4), and 5 months (n = 6). Control animals had no 
shunt. The following mechanisms of pulmonary vasorelaxation were stud- 
ied in isolated pulmonary artery rings (4 rings from each dog): (1) 
endothelium-dependent cyclic guanosine monophosphate-mediated relax- 
ation (response to acetylcholine), (2) endothelium-independent cyclic 
guanosine monophosphate-mediated r laxation (response to sodium nitro- 
prusside), and (3) iß-adrenergic yclic adenosine monophosphate-mediated 
relaxation (response to isoproterenol). Stastical analysis was done by 
analysis of variance. This model of high pulmonary flow did not produce an 
increase in pulmonary arterial pressure or transpulmonary gradient. 
However, chronic high pulmonary flow produced progressive dysfunction f 
all three of these mechanisms of pulmonary vasorelaxation. By 5 months of 
high pulmonary flow, acetylcholine produced only 36% ± 6% relaxation 
versus 95% -4-- 5% in control animals (p < 0.05). Likewise, sodium 
nitroprusside produced only 69% ± 6% relaxation versus 100% in control 
animals (p < 0.05). Finally, isoproterenol produced only 55% ± 5% 
relaxation versus 94% - 6% in control animals (p < 0.05). We conclude 
that dysfunction of the mechanisms of pulmonary vasorelaxation may 
contribute to exaggerated perioperative pulmonary vasoconstriction i  the 
setting of chronie high puimonary blood flow. (J THORAC CARDIOVASC SURG 
1996;111:190-7) 
David A. Fullerton, MD, Max B. Mitchell, MD, Darrell N. Jones, PhD, 
A. Maki, MD, and Robert C. McIntyre, Jr., MD, Denver, Colo. 
p ulmonary hypertension as a result of increased 
pulmonary vascular esistance (PVR) remains a 
significant problem in the treatment of patients 
undergoing surgical correction of left-to-right intra- 
cardiac shunts. Such pulmonary hypertension is one 
of the most important determinants ofperioperative 
morbidity and mortality and of long-term survival 
after cardiac operations. 1' 2 The structural changes 
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produced in the pulmonary vascular bed as a result 
of a left-to-right shunt are well recognized and 
clearly contribute to the development of such pul- 
monary hypertension. 3'4 However, eren patients 
undergoing surgical repair of a left-to-right shunt 
without advanced pulmonary vascular disease may 
exhibit significant pulmonary vasoconstriction in the 
perioperative period. 5
Net pulmonary vascular tone results from the 
balance of the mechanisms of pulmonary vasorelax- 
ation and vasoconstriction. If the mechanisms of 
pulmonary vasorelaxation are impaired, the net 
pulmonary vascular tone may be tipped in favor 
of pulmonary vasoconstriction. I  addition, impair- 
ment of the mechanisms of pulmonary vasorelax- 
ation may result in an exaggerated pulmonary vaso- 
constricting response to circulating or local 
vasoconstricting a onists. 6 
The principal intracellular mechanisms of pulmo- 
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Fig. 1. Mechanisms ofpulmonary vasorelaxation re ultimately mediated through either cGMP or A . 
cGMP is generated when guanylate cyclase is stimulated by endothelium-derived nitric oxide (NO) or by 
nitric oxide donors such as sodium nitroprusside (SNP). cAMP is generated when adenylate cyclase is 
stimulated by receptors such a  /3-adrenergic receptors (/3) in response to isoproterenol (ISO). ACh, 
Acetylcholine; M, muscarinic receptor. 
nary vasorelaxation are ultimately mediated through 
either guanosine Y,5'-cyclic monophosphate (cGMP) 
or adenosine Y,5'-cyclic monophosphate (cAMP). 7 
As shown in Fig. 1, cGMP-mediated pulmonary 
vasorelaxation may be achieved through pathways 
that are endothelium-dependent or endothelium- 
independent. Agents such as acetylcholine achieve 
endothelium-dependent cGMP-mediated pulmo- 
nary vasorelaxation byactivating muscarinic recep- 
tors on the endothelial cell, causing the synthesis 
and release of nitric oxide, which acts on guanylate 
cyclase in the subjacent pulmonary vascular smooth 
muscle cell to generate cGMP. Nitrovasodilators 
such as sodium nitroprusside relax pulmonary 
vascular smooth muscle by direct stimulation of 
pulmonary vascular smooth muscle guanylate cy- 
clase to generate cGMP. On the other hand, 
agents that are mediated through cAMP, such as 
• r i lsoproterenol, do so by activating 131-adrenergic 
membran~ receptors on the pulmonary vascular 
smooth muscle cell, leading to activation of ad- 
enylate cyclase and generation of cAMP. The 
mechanisms by which cGMP and cAMP ulti- 
mately achieve relaxation of pulmonary vascular 
smooth muscle are as yet unclear. 
We hypothesized that chronic high pulmonary 
arterial blood flow as produced by a left-to-right 
shunt produces dysfunction of the mechanisms of 
pulmonary vasorelaxation. Therefore the purpose of
this study was to examine the following mechanisms 
of pulmonary vasorelaxation i  a canine model of 
a left-to-right shunt: (1) endothelium-dependent 
cGMP-mediated pulmonary vasorelaxation (re- 
sponse to acety!choline), (2) endothelium-indepen- 
dent cGMP-mediated pulmonary vasorelaxation 
(response to sodium nitroprusside), and (3) /3-ad- 
renergic AMP-mediated pulmonary vasorelaxation 
(response to isoproterenol). 
The results of this study suggest that in the setting 
of chronic high pulmonary blood flow, there is a 
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Fig. 2. Experimental protocol. After creation of left-to-right shunt, pulmonary vasomotor control 
mechanisms were studied at 3 days, 2 weeks, and 5 months. 
progressive impairment of both cGMP- and cAMP- 
mediated mechanisms of pulmonary vasorelaxation. 
Methods 
All animals received humane care in compliance with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laborat0ry Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Experimental protoeol. Male mongrel dogs (20 to 25 
kg) were studied. Animals were quarantined in light- 
cycled rooms in the Animal Care Center of the University 
of Colorado and allowed dog food and water ad libitum. 
Creation of left-to-right shunt. Animals were placed in 
the supine position and halothane general anesthesia and 
endotracheal intubation institute& With use of a strict 
sterile technique, bilateral groin incisions were made and 
the femoral arteries and femoral veins were surgically 
isolated. After systemic heparinization, bilateral femoral 
arteriovenous fi tulas were created with the use of 6 mm 
synthetic tube conduits* anastomosed with fine monofil- 
ament suture. The fistulas were created in the shape of a 
gentle loop 6 inches in length. The patency of the con- 
duits was assured at the end of the surgical procedure 
with Doppler ultrasonographic evaluation. The surgical 
wounds were closed in appropriate layers and the animals 
recovered from the surgical procedure in the Animal Care 
Facility of the University of Colorado. The animals re- 
ceived long-term care in the Animal Care Facility in quiet, 
humidified, light-cycled rooms and were allowed ad libi- 
tum access to food and water up to the time of experi- 
mentation. Animals were killed at the following points 
after creation of the left-to-right shunt: 3 days (n = 2 
dogs), 2 weeks (n = 4 dogs), and 5 months (n = 5 dogs). 
Control animals (n = 5 dogs) were mongrel dogs of the 
same size that did not have creation of a left-to-right shunt 
(Fig. 2). 
Animal data collection. Before induction of general 
anesthesia, the patency of each fistula was assured with 
*Gore-Tex brand polytetrafluoroethylene conduit. Gore-Tex is a 
registered trademark of W. L. Gore & Associates, Inc., 
Newark, Del. 
Doppler ultrasonographic evaluation. After induction of 
general endotracheal nesthesia (halothane) and institu- 
tion of mechanical ventilation, a pulmonary arterial cath- 
eter (Abbot Laboratories, Chicago, Ill.) was placed via the 
right internal jugular vein. Mechanical ventilator settings 
were fraction of inspired oxygen 0.5, tidal volume 10 
ml/kg, and rate 10 breaths/min. A median sternotomy was 
done. A pressure-monitoring catheter was introduced into 
the left atrium via the right superior pulmonary vein. 
Likewise a catheter was placed in the aortic root for 
continuous monitoring of arterial pressure. 
With the animal in a steady-state condition, the follow- 
ing hemodynamic variables were measured and recorded: 
mean aortic pressure, pulmonary arterial pressure (mean, 
systolic, diastolic), and left atrial pressure. These data 
were used to calculate the transpulmonary gradient, whieh 
was used as a parameter of PVR. To calculate the 
magnitude of the left-to-right shunt by oximetric data, 
blood specimens were drawn simultaneously from the 
aortic root, main pulmonary artery, superior vena cava, 
and left atrium for blood gas determination. Blood gas 
specimens were collected in 1 ml heparinized glass sy- 
ringes with stritt attention paid to ensure the blood 
specimens were collected without exposure to atmo- 
sphere. These syringes of blood were immediately placed 
on ice and blood gas oxygen saturation was immediately 
determined (Radiometer OSM 3, Copenhagen, Den- 
mark). 
The animals were then systemically heparinized (250 
units/kg). Ten minutes after heparinization, the right lung 
was surgically explanted, and the animals were killed with 
an injection of intravenous KC1. Pulmonary arterial rings 
were eut from the explanted lung. 
Pulmonary artery ring preparation. With the use of a 
dissecting microscope, four third-order pulmonary arter- 
ies (approximately 1 mm diameter) were dissected from 
each lung (2 pulmonary arteries were dissected from the 
upper lobe and 2 pulmonary arteries were dissected from 
the lower lobe). Under dissecting microscope magnifica- 
tion, the surrounding tissue was gently dissected away 
from the pulmonary arteries. The pulmonary arteries were 
then each cut into rings 3 to 4 mm wide. Great care was 
taken during this process to avoid stretching the vessel, 
which might cause endothelial injury. The pulmonary 
arterial rings were suspended on fine wire tensiometers in 
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Tab le  I. Oximetric and hemodynamic data 
Control 3 Days 2 Wk 5 Mo 
S A 0 2 (OB) 100 100 100 100 
Ssv O s (%) 65 -+ 4 63 -+ 5 62 -+ 5 63 -+'5 
SpA O s (%) 71 --+ 2 92 --+ 2 92 --+ 2 91 --+ 3 
Spv O; (%) 100 100 100 100 
pH 7.38 + 0.03 7.39 -+ 0.03 7.38 -+ 0.02 7.38- + 0.03 
Hemoglobin (gm/dl) 13 ± 3 14 -+ 3 13 _+ 2 13 ± 3 
MAP (mm Hg) 74 -+ 6 76 + 8 72 -+ 4 75 ± 4 
PAS (mm Hg) 20 ± 1 20 -+ 2 19 -+ 2 20 ± 2 
PAD(mmHg) 12_+1 12_+1 12_+1 11_+1 
PAM(mmHg) 15_+1 15_+1 14_+1 14± ! 
LAP(mmHg) 3-+1 3±1 3±i  3_+ 1 
TPG(mmHg) 12±1 12_+ 1 11_+1 11_+1 
Values are mean plus or minus tandard error of the mean. SA O» Aortic blood saturation; Ssv O» superior vena cava blood saturation; Sp,~ 02, pulmonary 
arterial blood saturation; S»v 02, pulmonary venous blood saturation; MAP, mean aortic blood pressure; PAS, systolic pulmonary artery pressure; PAD, 
diastolic pulmonary artery pressure; PAM, mean pulmonary artery pressure; LAP, left arterial pressure; TPG, transpulmonary g adient. 
individual 10 ml organ chambers. The organ chambers 
were surrounded by water jackets and continually warmed 
to 37 °C. Ring tension was determined by use of a 
force-displacement transducer (Grass FTO3, Grass In- 
struments :Co., Quincy, Mass.) attached to each tensiom- 
eter apparatus. Force displacement was recorded at 0.67 
Hz with use of a MacLab Data Interface Module (ADI 
Instruments, Milford, Mass,) on a Macintosh IIci com- 
puter (Apple Inc., Cupertino, Calif.). The organ chambers 
were filled with Earle's balanced salt solution and contin- 
uously bubbled with gas composed of 21% oxygen, 5% 
carbon di0xide, and balanced nitrogen, producing an 
oxygen tension (Po2) of 110 to 115 mm Hg and a pH of 
7.36 to 7.40. Earle's balanced salt solütion is a standard 
physiologic salt solution and contains CaC12 1.80 mmol/L, 
MgSO 4 (anhydrous) 0.83 mmol/L~ KC15.36 mmol/L, NaC1 
116.34 mmol/L, NaPO 4 0.40 mmol/L (dibasic), D-glucose 
5.50 mmol/L, NaHCO 3 19.04 mmol/L, and phenol red Na 
0.03 mmolYL (as pH indicator), 
J . . • 
The opttmal restmg tension (passive load) of pulmonary 
arterial rings of this size was determined to be 750 mg in 
a separate series of experiments in which isolated pulmo- 
nary arterial rings were suspended at passive loads ranging 
from 500 mg to 1000 mg before phenylephrine 10 .8 mol/L 
was addedl to the organ chamber bäth. The passive load 
tension that resulted in the highest tension generated in 
response tp phenylephrine was 750 mg. Therefore, for 
subsequen~ studies, a passive load of 750 mg tension was 
used. The rings were suspended at a tension of 750 mg for 
90 mlnuteß, durmg whach tlme the Earle's balanced salt 
solution was changed in each organ chamber every 15 
minutes. A given ring was preconstricted with phenyleph- 
rine i0 -8 ~ol/L to a tension of 350 to 400 mg There was 
no differer~ce in response to phenylephrine among the 
groups stußied. Once the ring tension reached a steady 
state in re~ponse to phenylephrine a given vasorelaxing 
agent was [added to the organ chamber. Acetylcholine, 
sodium nitroprusside, and isoproterenol have each previ- 
ously been! shown to achieve maximal relaxation to •he- 
• I . . . .  x 
nylephrme+induced pulmonary arterlal ring tenslon at a 
dose of 1Ò -6 mol/L.S ,9 The vasorelaxing responses to 
acetylcholine 10 .6 mol/L, sodium nitroprusside 10 ó 
mol/L, and isoproterenol 10 .6 mol/L were then deter- 
mined in each ring in random order. After each agent was 
tested, the organ chambers were flushed severa] times and 
the rings allowed to reach a steady state again before the 
rings were once again preconstricted with phenylephrine 
to test the next vasorelaxing agent. Four pulmonary 
arterial rings from each lung were studied at each time of 
data col!ection. 
Mathematical formulas 
Transpulmonary gradient (millimeters of mercury) = 
Mean pulmonary artery pressure 
- Left atrial pressure 
(1) 
Left-to-right shunt (pulmonic flow/systemic flow) = 
Aortic saturation (percent) - 
Superior vena cava saturation (percent) 
Pulmonary venous aturation (percent) - (2) 
Pulmonary arterial saturation (percent) 
Statistical analyses. Statistical analyses were done with 
a Macintosh Quadra 650 computer (Apple Inc.) and 
StatView software (Brain Power, Inc., Calabasas, Calif.). 
Data are presented as mean plus or minus 1 standard 
error of the mean of the number of pulmonary rings 
studied at each point of data coliection. Four pulmonary 
artery rings were obtained from each animal, and the 
number of animals tudied at each point of data collection 
is shown in Fig. 2. Statistical eva!,uation used standard 
one-way analysis of variance with post-hoc Bonferroni- 
Dunn test. A p value of less than 0.05 was accepted as 
statiStically significant. 
Resu l ts  
Al l  dogs survived without compl icat ion up to the 
designated t ime of study. As calculated by the 
oximetric data, this modet produce d approximately 
a 3:1 left-to-r ight shunt (Table I). Thus this model  
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Fig. 3. Endothelial-dependent cGMP-mediated pulmonary vasorelaxation (response to acetylcholine). 
There was significant impairment of this mechanism at 2 weeks, which was further impaired at 5 months. 
Values are mean plus or minus standard error of mean. *p < 0.05 versus control values. 
created a shunt of sufficient magnitude to be con- 
sidered clinically significant. 
Over the time course of this study, this shunt did 
not produce pulmonary hypertension. As shown in 
Table I, there was no difference in pulmonary 
arterial systolic, diastolic, or mean pressure at any of 
the points in data collection. Likewise, there were 
no changes in left atrial pressure. Thus the transpul- 
monary gradient did not change (Table I). 
There was a progressive dysfunction of endothe- 
lium-dependent cGMP-mediated pulmonary va- 
sorelaxation (response to acetylcholine). As shown 
in Fig. 3, acetylcholine 10 .6 mol/L produced 95% + 
5% relaxation of pulmonary arterial rings in control 
specimens. This was not different at 3 days. How- 
ever, at 2 weeks, acetylcholine 10 .6 mol/L produced 
only 84% _+ 5% relaxation (p < 0.05 versus control 
value). At 5 months, this mechanism of pulmonary 
vasorelaxation was significantly impaired and acetyl- 
choline 10 .6 mol/L produced only 36% _+ 6% 
relaxation (p < 0.05 versus control value). 
Likewise, there was progressive dysfunction of 
endothelium-independent cGMP-mediated pulmo- 
nary vasorelaxation (response to sodium nitroprus- 
side). As shown in Fig. 4, the vasorelaxing response 
to sodium nitroprusside 10 .6 mol/L was not differ- 
ent from control values at 3 days or at 2 weeks. 
However, by 5 months, there was significant impair- 
ment of this mechanism and sodium nitroprusside 
10 -6 mol/L produced only 69% _+ 6% relaxation 
versus 100% relaxation in control specimens (p < 
0.05 versus control value). 
The third mechanism of pulmonary vasodilation 
studied was /3-adrenergic cAMP-mediated pulmo- 
nary vasorelaxation (response to isoproterenol). As 
shown in Fig. 5, there was no dysfunction of this 
mechanism at 3 days. However, at 2 weeks, this 
mechanism was significantly impaired and isoproter- 
enol produced only 62% +_ 7% relaxation versus 
95% _+ 6% relaxation in control specimens (p < 0.05 
versus control value). At 5 months, this mechanism 
was further impaired and isoproterenol produced 
only 55% + 5% relaxation (p < 0.05 versus control 
value). 
Discuss ion 
Net pulmonary vascular tone results from the 
balance of the mechanisms of pulmonary vasorelax- 
ation and vasoconstriction. I  the normal ung, the 
low pulmonary vascular smooth muscle tone may at 
least in part be due to the basal endothelial release 
of the vasodilator nitric oxide. 6 Endothelium-de- 
rived nitric oxide lowers pulmonary vascular tone by 
stimulating uanylate cyclase in subjacent vascular 
smooth muscle cells to generate cGMP, which pro- 
duces pulmonary vascular smooth muscle relax- 
ation. 1° If the mechanisms of pulmonary vasorelax- 
ation are impaired, the net pulmonary vascular tone 
may be tipped in favor of pulmonary vasoconstric- 
tion. In addition, impairment of the mechanisms of 
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Fig. 4. Endothelium-independent cGMP-mediated pulmonary vasorelaxation (response to sodium nitro- 
prusside). This mechanism of pulmonary vasorelaxation was significantly impaired at 5 months. Values are 
mean plus or minus tandard error of mean. *p < 0.05 versus control values. 
pulmonary vasorelaxation may result in an exagger- 
ated pulmonary vasoconstricting response to circu- 
lating or local vasoconstricting a onists. ó In addition 
to cGMP~mediated relaxation, the other principal 
intracelluiar mediator of pulmonary vasorelaxation 
is cAMP. 7 The results of this study suggest that both 
cGMP- and cAMP-mediated mechanisms ofpulmo- 
nary vasarelaxation become dysfunctional in the 
setting of a left-to-right shunt. 
Other large animal models have been used to 
create structural changes in the pulmonary circula- 
tion as a result of a left-to-right shunt. However, the 
changes in pulmonary vasomotor control mecha- 
nisms caused by chronic high pulmonary blood flow 
have not previously been described. Creation of an 
aortopulmonary arterial anastomosis in pigs 1~' 22 or 
dogs13, 14 rapidly produces muscular changes in the 
pulmonaPj vasculature that resemble the changes 
found in i human beings with left-to-right shunts. 
These large animal models increase both pulmonary 
arterial p~essure and flow. By simultaneously chang- 
ing both Of these injurious stimuli, it is difficult o 
separate the effects of pressure from those of flow. 
The model used in the present study offered an 
advantage by creating high pulmonary flow without 
pulmonaßl hypertension. This permitted an exami- 
nation of the influence of high pulmonary flow alone 
on pulmonary vasomotor control mechanisms. 
However, certain limitations of this model must 
be acknoWledged. First, this model was not an 
intracardiac shunt. It is possible that a model in 
which an intracardiac shunt was created might have 
yielded higher pulmonary arterial pressure or a 
different pattern of pulmonary vasomotor dysfunc- 
tion. Second, the hemodynamic measurements w re 
by necessity made with the animals under general 
anesthesia. It is therefore possible that a small 
increase in pulmonary arterial pressure was present 
in these animals but not measurable under general 
anesthesia. Third, the animals used in the present 
study were mature. In the clinical situation, the 
left-to-right shunt is present from birth. Fourth, 
generation of high pulmonary artery blood flow by 
creation of a left-to-right shunt unavoidably raises 
the Po 2 of the pulmonary arterial blood; it is impos- 
sible to determine what influence, if any, the in- 
creased Po 2 had in the production of pulmonary 
vasomotor dysfunction. Because of some of these 
limitations, it may not be possible to directly extrap- 
olate the findings of the present study to human 
beings. Nonetheless, the findings of the present 
study do suggest that chronic high pulmonary flow 
produces dysfunction of the mechanisms of pulmo- 
nary vasorelaxation. 
The structural changes produced in the pulmo- 
nary circulation as a result of chronic high pulmo- 
nary arterial flow have been well characterized. In 
1958, Heath and Edwards 4 described the progres- 
sion of changes beginning with the reversible 
changes of intimal hyperplasia and medial hypertro- 
phy and progressing to he irreversible changes of 
angiomatous malformation and fibrinoid necrosis. 
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Fig. 5. /3-Adrenergic cAMP-mediated pulmonary vasorelaxation (response toisoproterenol). This mech- 
anism of vasorelaxation was significantly impaired by 2 weeks. Values are mean plus or minus tandard 
error of mean, *p < 0.05 versus control values. 
The mechanisms by which these changes are pro- 
duced remain unclear. Most current heories invoke 
endothelial cell injury by high pulmonary flow and 
pressure as an inciting event. Endothelial cell injury 
may result in release of proteases into the subendo- 
thelium, leading to destruction of the basement 
membrane and extracellular matrix proteins. This in 
turn may trigger both hypertrophy and hyperplasia 
of pulmonary vascular smooth muscle cells, leading 
to increased muscularization f small vessels. 15' 16 
These structural changes have been cleärly associ- 
ated with progressively increasing pulmonary arte- 
rial pressure. 17' 18 
Pulmonary hypertension as a result of an in- 
creased PVR may greatly complicate the periopera- 
tive treatment ofpatients undergoing correction of a 
left-to-right shunt. This pulmonary hypertension 
may be derived from the structural changes of the 
pulmonary circulation. However, in addition, the 
pulmonary circulation of these patients i  character- 
ized by a "reactive" or an exaggerated vasoconstric- 
tive component of PVR. 16 The mechanisms of this 
exaggerated pulmonary vasoconstriction are un- 
clear, but circulating or local vasoconstricting a o- 
nists such as catecholamines, 19 thromboxanes, 2° leu- 
kotrienes, 21and other pulmonary vasoconstricting 
agonists 22 may all contribute. The most extreme 
example of this exaggerated pulmonary vasocon- 
striction is a "pulmonary hypertensive crisis," in 
which severe pulmonary vasospasm is refractory to 
vasodilator therapy and may by lethal. 
Rather than examining the pulmonary vascular 
structural changes induced by high pulmonary blood 
flow, the present study focused instead on intrinsic 
mechanisms of pulmonary vasomotor control: 
cGMP-mediated and cAMP-mediated pulmonary 
vasorelaxation. The findings of the present study 
demonstrated progressive dysfunction ofboth endo- 
thelium-dependent and endothelium-independent 
cGMP-mediated pulmonary vasorelaxation and 
/3-adrenergic cAMP-mediated pulmonary vasorelax- 
ation in a canine model of a left-to-right shunt. 
Although these signal transduction pathways were 
shown to become dysfunctional, the present study 
does not elucidate xactly where in these pathways 
the impairment was produced. This pulmonary va- 
somotor dysfunction occurred before the develop- 
ment of pulmonary hypertension or an increase in 
transpulmonary gradient. The present study did not 
examine what structural changes, if any, were pro- 
duced in the pulmonary vascular bed. However, 
because the animals in the present study did not 
have pulmonary hypertension, it is tempting to 
speculate that the impairment in pulmonary vasore- 
laxation preceded structural changes. 
The current findings may offer some mechanistic 
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insight into the development of pulmonary hyper- 
tension with chronic high pulmonary blood flow. 
The present study demonstrated significant progres- 
sive impairment of cGMP- and cAMP-mediated 
mechanisms of pulmonary vasorelaxation in the 
setting of a left-to-right shunt. Such dysfunction of 
vasorelaxation may help tip the net balance of 
pulmonary vasomotor tone toward vasoconstriction 
and contribute to exaggerated pulmonary vasocon- 
striction in response to local or circulating vasocon- 
stricting agonists. 
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